Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE
Authors
Siriwardena, AKSerrablo, A
Fretland, Å
Wigmore, SJ
Manuel-Angel, J
Malik, HZ
Stättner, S
Soreide, K
Zmora, O
Meijerink, M
Kartalis, N
Lesurtel, M
Verhoef, K
Balakrishnan, A
Gruenberger, T
Jonas, E
Devar, J
Jamdar, S
Jones, R
Abu Hilal, M
Andersson, B
Boudjema, K
Mullamitha, Saifee
Stassen, L
Dasari, BVM
Frampton, AE
Aldrighetti, L
Pellino, G
Buchwald, P
Gürses, B
Wasserberg, N
Gruenberger, B
Spiers, HVM
Jarnagin, W
Vauthey, JN
Kokudo, N
Tejpar, S
Valdivieso, A
Adam, R
Joint European African Hepato, P
European Soc Surgical Oncology, ESS
European Soc Coloproctology, E
European Soc Gastrointestinal, A
Cardiovasc Interventional, R
Affiliation
Oncology Department, Christie Hospital, Manchester, UKIssue Date
2023
Metadata
Show full item recordAbstract
Background: Contemporary management of patients with synchronous colorectal cancer and liver metastases is complex. The aim of this project was to provide a practical framework for care of patients with synchronous colorectal cancer and liver metastases, with a focus on terminology, diagnosis, and management. Methods: This project was a multiorganizational, multidisciplinary consensus. The consensus group produced statements which focused on terminology, diagnosis, and management. Statements were refined during an online Delphi process, and those with 70 per cent agreement or above were reviewed at a final meeting. Iterations of the report were shared by electronic mail to arrive at a final agreed document comprising 12 key statements. Results: Synchronous liver metastases are those detected at the time of presentation of the primary tumour. The term 'early metachronous metastases' applies to those absent at presentation but detected within 12 months of diagnosis of the primary tumour, the term 'late metachronous metastases' applies to those detected after 12 months. 'Disappearing metastases' applies to lesions that are no longer detectable on MRI after systemic chemotherapy. Guidance was provided on the recommended composition of tumour boards, and clinical assessment in emergency and elective settings. The consensus focused on treatment pathways, including systemic chemotherapy, synchronous surgery, and the staged approach with either colorectal or liver-directed surgery as first step. Management of pulmonary metastases and the role of minimally invasive surgery was discussed. Conclusion: The recommendations of this contemporary consensus provide information of practical value to clinicians managing patients with synchronous colorectal cancer and liver metastases.Citation
Siriwardena AK, Serrablo A, Fretland Å, Wigmore SJ, Manuel-Angel J, Malik HZ, et al. Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE. BRITISH JOURNAL OF SURGERY. 2023 2023 JUL 14. PubMed PMID: WOS:001074938200001. English.Journal
British Journal Of SurgeryDOI
10.1093/bjs/znad124PubMed ID
37442562Additional Links
https://dx.doi.org/10.1093/bjs/znad124Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/bjs/znad124
Scopus Count
Collections
Related items
Showing items related by title, author, creator and subject.
-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)Lyon, A. R.; Lopez-Fernandez, T.; Couch, L. S.; Asteggiano, R.; Aznar, Marianne Camille; Bergler-Klein, J.; Boriani, G.; Cardinale, D.; Cordoba, R.; Cosyns, B.; et al. (2022)
-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)Lyon, A. R.; Lopez-Fernandez, T.; Couch, L. S.; Asteggiano, R.; Aznar, Marianne Camille; Bergler-Klein, J.; Boriani, G.; Cardinale, D.; Cordoba, R.; Cosyns, B.; et al. (2022)None
-
Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European association of urology, European society for radiotherapy and oncology, and European society of medical oncology genitourinary facultyBamias, A.; Stenzl, A.; Brown, S. L.; Albiges, L.; Babjuk, M.; Birtle, A.; Briganti, A.; Burger, M.; Choudhury, Ananya; Colecchia, M.; et al. (2023)Background: In contrast to other cancers, the concept of oligometastatic disease (OMD) has not been investigated in bladder cancer (BC). Objective: To develop an acceptable definition, classification, and staging recommendations for oligometastatic BC (OMBC) spanning the issues of patient selection and the roles of systemic therapy and ablative local therapy. Design, setting, and participants: A European consensus group of 29 experts, led by the European Association of Urology (EAU), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Medical Oncology (ESMO), and including members from all other relevant European societies, was established. Outcome measurements and statistical analysis: A modified Delphi method was used. A systematic review was used to build consensus questions. Consensus statements were extracted from two consecutive surveys. The statements were formulated during two consensus meetings. Agreement levels were measured to determine if consensus was achieved (≥75% agreement). Results and limitations: The first survey included 14 questions and the second survey had 12. Owing to a considerable lack of evidence, which was the major limitation, definition was limited in the context of de novo OMBC, which was further classified as synchronous OMD, oligorecurrence, and oligoprogression. A maximum of three metastatic sites, all resectable or amenable to stereotactic therapy, was proposed as the definition of OMBC. Pelvic lymph nodes represented the only "organ" not included in the definition of OMBC. For staging, no consensus on the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography was reached. A favourable response to systemic treatment was proposed as the criterion for selection of patients for metastasis-directed therapy. Conclusions: A consensus statement on the definition and staging of OMBC has been formulated. This statement will help to standardise inclusion criteria in future trials, potentiate research on aspects of OMBC for which consensus was not achieved, and hopefully will lead to the development of guidelines on optimal management of OMBC.